Drug Reprofiling: A Prospective Approach to Battle Chronic Ailments

Natasha Naval Aggarwal; S.M. Sindhoor; N. Raghavendra Naveen; Buduru Gowthami; Prajitha Biju

doi:10.1055/s-0043-1769903

Journal of Health and Allied Sciences NU, Inhaltsverzeichnis

CC BY 4.0 · Journal of Health and Allied Sciences NU 2024; 14(01): 038-046
DOI: 10.1055/s-0043-1769903

Review Article

Drug Reprofiling: A Prospective Approach to Battle Chronic Ailments

Natasha Naval Aggarwal

¹Department of Pharmachemistry, Yenepoya Pharmacy College and Research Center, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India

,

S.M. Sindhoor

²Department of Pharmaceutics, P.A College of Pharmacy, Nadupadav, Montepadav Post, Kairangala, Mangalore, Karnataka, India

,

N. Raghavendra Naveen

³Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, Mangaluru

,

Buduru Gowthami

⁴Department of Pharmaceutics, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhra Pradesh, India

,

Prajitha Biju

⁵Department of Pharmaceutics, Yenepoya Pharmacy College & research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India

› Institutsangaben

Abstract

The concept of drug “reprofiling” has garnered attention in the recent past post the outbreak of coronavirus disease 2019 when traditional drug discovery seemed to fail. Even though repurposing is called pharma-friendly in terms of monetary relief, clinical trials play an integral role in repurposed nontarget /combination moieties. Nevertheless, when a drug exhibits no returns to the market, an exhaustive study on mechanism of action (MOA) can help for reprofiling of drugs for new indications. However, several papers have claimed that scarcity of resources and data access, and staffing issues, tends to pull down reprofiling of drugs. In contrast to this notion, a total of 155 patented articles to date give a strong base for drug repurposing. In the present review, a scientific prospection of reprofiled antifungal and antiviral agents for the past decade was made using the PubMed database wherein a total of 410 and 768 publications have resulted respectively. The authors have attempted to focus their attention to repurposing antifungal drugs for chronic ailments and infectious diseases by understanding their MOA.

For example, antifungal azoles, which work by blocking ergosterol synthesis, can be repurposed as they inhibit histone deacetylase as well significantly decrease the production of cytokines and modulate the inflammatory pathways used by cancer cells.

Hence, we believe that the mentioned Food and Drug Administration-approved drug candidates can be utilized to treat nontarget diseases, notably rare/neglected diseases as well as chronic illnesses and the more recent viral infections that are spreading globally.

Keywords

antibiotic - FDA-approved - tumors

Volltext

Referenzen

References
1 Rajagopal K, Byran G, Jupudi S, Vadivelan R. Activity of phytochemical constituents of black pepper, ginger, and garlic against coronavirus (COVID-19): an in silico approach. Int J Heal Allied Sci 2020; 9: 43-50
2 Michael ML, Moses JA. Characterization of silver nanoparticles synthesized using Ocimum Basilicum seed extract. Lett Appl NanoBio Science 2021; 11: 3411-3420
3 Dave K. Bioengineering a cadmium sensing green fluorescent protein based whole-cell biosensor from Pseudomonas aeruginosa. Proc. Int. 2020; 2: 2032-2043
4 Eastman RT, Roth JS, Brimacombe KR. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020; 6: 672-683
5 Mulangu S, Dodd LE, Davey Jr RT. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303
6 Jordan R. et al. Broad-spectrum investigational agent GS-5734 for the treatment of Ebola, MERS coronavirus and other pathogenic viral infections with high outbreak potential. Open Forum Infect Dis 2017; 4 (Suppl. 01) S737
7 Koch S, Pong W. First up for COVID-19: nearly 30 clinical readouts before end of April. Accessed March 21, 2023 at: https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months
8 Riva L. et al. A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv 2020 2020.04.16.044016
9 Van der Jeught K, Xu H, Li Y, Lu X, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24: 3834-3848
10 Pushpakom S, Iorio F, Eyers P. et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18: 41-58
11 Napolitano F, Zhao Y, Moreira VM. et al. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013; 5 (01) 30
12 Pirone L, Gatto AD, Gaetano SD. et al. A multi-targeting approach to fight SARS-CoV-2 attachment. Front Mol Biosci 2020; 7: 1-5
13 Vincent MJ, Bergeron E, Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 69: 2-10
14 Sumudu P, Leelananda SP. Computational methods in drug discovery. Beilstein J Org Chem 2016; 12: 2694-2718
15 Zhu N. A novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 382: 727-733
16 Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharm 2018; 15: 4311-4313
17 Shi J, Zhou L, Huang HS. et al. Repurposing oxiconazole against colorectal cancer via PRDX2-mediated autophagy arrest. Int J Biol Sci 2022; 18: 3747-3761
18 Islam MM, Naveen NR, Anitha P. et al. The race to replace PDE5i: recent advances and interventions to treat or manage erectile dysfunction: evidence from patent landscape (2016–2021). J Clin Med 2022; 11: 3140
19 A Study in Patients with Erectile Dysfunction—Full Text View. Accessed March 21, 2023 at: https://clinicaltrials.gov/ct2/show/NCT01122264?cond=erectile+dysfunction&phase=3&draw=5&rank=1
20 Custodio MM, Sparks J, Long TE. Disulfiram: A repurposed drug in preclinical and clinical development for the treatment of infectious diseases. Antiinfect Agents 2022; 20 (03) e040122199856
21 Weng N, Qin S, Liu J. et al. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2022; 12: 3085-3102
22 Prado-Carrillo O, Arenas-Ramírez A, Llaguno-Munive M. et al. Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells. Int J Mol Sci 2022; 23: 7715
23 Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 2013; 4: 66-71
24 Gupta Y, Goicoechea S, Romero JG. et al. Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: integration of in vitro testing, pharmacological corroboration, and mechanisms of action. Yao Wu Shi Pin Fen Xi 2022; 30 (01) 128-149
25 DeSarno AE, Parcell BJ, Coote PJ. Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae. Pathog Dis 2020; 78 (09) ftaa063
26 A phase I trial of nelfinavir (viracept) in adults with solid tumors. Accessed March 21, 2023 at: https://clinicaltrials.gov/ct2/show/record/NCT01445106?term=anti+viral&cond=drug+repurposing&draw=2&rank=2
27 Gewili N, Abdelghany AM, Mekhaimer M, Oraby A. Synthesis and optical properties of chitosan/polypyrrole composite for biological applications. Lett. Appl NanoBioScience 2021; 10: 2742-2749
28 Banerjee A, Sarkar A, Acharya K, Chakraborty N. Nanotechnology: an emerging hope in crop improvement. Lett Appl NanoBioScience 2021; 10: 2784-2803
29 Novindriani D, Novindriana D, Wijianto B, Andrie M. Studies on the Sedative Effect of Mitragyna Speciosa Korth. as an Endemic Plant in West Borneo, Indonesia. Lett. Appl . NanoBioScience 2021; 11: 3344-3349
30 Bakr A. Purification and characterization of milk clotting enzyme from edible mushroom (Pleurotus Florida). Lett. Appl . NanoBioScience 2021; 11: 3362-3373
31 Gameiro GR, Sinkunas V, Liguori GR, Auler-Júnior JOC. Precision medicine: changing the way we think about healthcare. Clinics (São Paulo) 2018; 73: e723
32 Odekunle FF. Association of PIK3CA and PTEN Genetic Alterations with Cervical Cancer Mortality and Tumor Recurrence (Doctoral dissertation, Rutgers The State University of New Jersey, Rutgers School of Health Professions)
33 Xue HJ, Li Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci 2018; 14: 1232-1244
34 Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev 2020; 40: 586-605
35 Farhana N. Meticulous Endorsement of Black Seed and Jambolana: A Scientific. Herbs and Spices: New Processing Technologies. 2021 Dec 1:165.
36 Barratt MJ, Frail DE. Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, New Jersey, United States: John Wiley & Sons; 2012. 01. 65-88
37 Oprea TI. Drug repurposing funding projects. Drug Discov Today Ther Strateg 2011; 8: 61-69
38 Cusinato J, Cau Y, Calvani AM, Mori M. Repurposing drugs for the management of COVID-19. Expert Opin Ther Pat 2021; 31: 295-307
39 Schenone M, Wagner BKP, Clemons A, Program B. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2017; 9 (04) 232-240
40 Kim JH. Antifungal drug repurposing. Antibiotics (Basel) 2020; 9: 1-29
41 Pavlopoulos GA, Wegener AL, Schneider R. A survey of visualization tools for biological network analysis. BioData Min 2008; 1: 1-11
42 Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012; 2012: 713687
43 Dixit H, Sharma A, Chandel V, Porte SM. Ayurvedic methods of diagnosis and management of Dadru Kushta W. S. R. to fungal infection. Int J Health Sci Res 2020; 10: 114-120
44 Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. Heliyon 2020; 6: e04663
45 Kim S. PubChem substance and compound databases. Nucleic Acids Res 2016; 44: 1202-1213